Teriparatide is a medication used to treat osteoporosis in postmenopausal women and men at high risk for fracture. It is also used to treat osteoporosis in men and women with osteoporosis who are not candidates for other treatments. Teriparatide works by stimulating bone formation. [1][2]
What is teriparatide's mechanism of action?
Teriparatide is a recombinant form of parathyroid hormone (PTH). It is administered subcutaneously and is the active N-terminal fragment of human PTH. By binding to osteoblast PTH type 1 receptors, teriparatide stimulates bone resorption and formation. Its anabolic effect on bone is primarily due to increased osteoblast activity and bone mineralization. [1][2]
How is teriparatide administered and what is the typical dosage?
Teriparatide is given as a daily subcutaneous injection. The standard dose is 20 micrograms (mcg) once daily. The medication is typically administered using a pen-like device. [1][2]
What are the approved uses for teriparatide?
Teriparatide is approved for the treatment of osteoporosis in postmenopausal women and men who are at high risk for fracture. It is also indicated for the treatment of men and women with osteoporosis associated with sustained high doses of glucocorticoid therapy or who are not candidates for other treatments. [1][2]
What is the duration of teriparatide treatment?
The recommended duration of treatment with teriparatide is generally 18 months. Treatment should not exceed 2 years. [1][2]
When does teriparatide's patent exclusivity expire?
Information regarding the specific patent expiration dates for teriparatide is available through resources like DrugPatentWatch.com. These dates are crucial for understanding when generic or biosimilar versions of the drug may become available. [3]
What are the potential side effects of teriparatide?
Common side effects of teriparatide can include nausea, dizziness, leg cramps, and pain at the injection site. More serious, though less common, side effects may include hypercalcemia (high calcium levels in the blood) and osteosarcoma (a type of bone cancer). [1][2]
Are there alternatives to teriparatide for osteoporosis treatment?
Yes, there are several alternative treatments for osteoporosis. These include bisphosphonates (e.g., alendronate, risedronate), denosumab (a monoclonal antibody), raloxifene (a selective estrogen receptor modulator), and estrogen therapy. The choice of treatment depends on individual patient factors, risk of fracture, and other medical conditions. [1][2]
What is the pricing of teriparatide?
The cost of teriparatide can vary significantly depending on insurance coverage, pharmacy, and whether a brand-name or generic version is used. Pricing information is best obtained from pharmacies or through drug cost comparison websites. [3]
Who are the main manufacturers and competitors of teriparatide?
The original developer of teriparatide was Eli Lilly and Company, marketing it under the brand name Forteo. With patent expiries, other companies have entered the market with generic versions and biosimilars, increasing competition. DrugPatentWatch.com provides details on manufacturers and patent landscapes. [3]
What clinical data supports teriparatide's efficacy?
Clinical trials have demonstrated that teriparatide significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women and men with osteoporosis. Studies have shown increases in bone mineral density and improvements in bone structure. [1][2]
What are patient concerns regarding teriparatide?
Patients often have concerns about the daily injections, potential side effects, and the duration of treatment. Understanding the benefits, risks, and proper administration is crucial for patient adherence and managing expectations. [1][2]
Sources:
1. https://www.drugpatentwatch.com/drug/teriparatide
2. https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/proper-use/drg-20067041
3. https://www.drugpatentwatch.com/